Tenascin-C stimulates glioma cell invasion through matrix metalloproteinase-12

Cancer Research

Volumn 66, Issue 24, 2006, Pages 11771-11780

  Sarkar, Susobhan ^a   Nuttall, Robert K ^b   Liu, Shuhong ^a   Edwards, Dylan R ^b   Yong, V Wee ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF EAST ANGLIA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DISINTEGRIN; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; METALLOPROTEINASE INHIBITOR; SMALL INTERFERING RNA; TENASCIN;

ARTICLE; CELL INVASION; CONTROLLED STUDY; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH;

BRAIN NEOPLASMS; CELL LINE, TUMOR; COLLAGEN; CULTURE MEDIA, CONDITIONED; DNA PRIMERS; GLIOMA; HUMANS; KINETICS; MATRIX METALLOPROTEINASE 12; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TENASCIN; TRANSFECTION;

EID: 33846253207     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0470     Document Type: Article

References (50)

1. Goldbnmner RH, Bernstein JJ, Tonn JC. ECM-mediated glioma cell invasion. Microsc Res Tech 1998;43:250-7.
2. Forsyth PA, Wong H, Laing TD, et al. Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. Br J Cancer 1999;79:1828-35.
3. Yong VW, Power C, Forsyth P, Edwards DR. Metal-loproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001;2:502-11.
4. VanMeter TE, Rooprai HK, Kibble MM, Fiffmore HL, Broaddus WC, Pilkington GJ. The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. J Neurooncol 2001;53:213-35.
5. Levicar N, Nuttall RK, Lan TT. Proteases in brain tumour progression. Acta Neurochir (Wien) 2003;145:825-38.
6. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003;3:489-501.
7. Yong VW. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 2005;6:931-44.
8. Fillmore HL, VanMeter TE, Broaddus WC. Membrane-type matrix metalloproteinases (MT-MMPs): expression and function during glioma invasion. J Neurooncol 2001;53:187-202.
9. Nuttall RK, Pennington CJ, Taplin J, et al. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res 2003;1:333-45.
10. Bellon G, Caulet T, Cam Y, et al. Immunohistochemical localisation of macromolecules of the basement membrane and extracellular matrix of human gliomas and meningiomas. Acta Neuropathol (Berl) 1985;66:245-52.
11. Paulus W, Roggendorf W, Schuppan D. Immunohistochemical investigation of collagen subtypes in human glioblastomas. Virchows Arch A Pathol Anat Hist 1988;413:325-32.
12. 131l-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 2005;46:1042-51.
13. Zamecnik J, Vargova L, Homola A, Kodet R, Sykova E. Extracellular matrix glycoproteins and diffusion barriers in human astrocytic tumours. Neuropathol Appl Neurobiol 2004;30:338-50.
14. Annabi B, Thibeault S, Moumdjian R, Beliveau R. Hyaluronan cell surface binding is induced by type I collagen and regulated by caveolae in glioma cells. J Biol Chem 2004;279:21888-96.
15. Higuchi M, Ohnishi T, Arita N, Hiraga S, Hayakawa T. Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis. Acta Neuropathol (Berl) 1993;85:481-7.
16. Ruiz C, Huang W, Hegi ME, et al. Differential gene expression analysis reveals activation of growth promoting signaling pathways by tenascin-C. Cancer Res 2004;64:7377-85.
17. Chintala SK, Sawaya R, Gokaslan ZL, Fuller G, Rao JS. Immunohistochemical localization of extracellular matrix proteins in human glioma, both in vivo and in vitro, Cancer Lett 1996;101:107-14.
18. Zagzag D, Friedlander DR, Miller DC, et al. Tenascin expression in astrocytomas correlates with angiogenesis. Cancer Res 1995;55:907-14.
19. Zagzag D, Shiff B, Jallo GI, et al. Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase. Cancer Res 2002;62:2660-8.
20. Leins A, Riva P, Lindstedt R, Davidoff MS, Mehraein P, Weis S. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer 2003;98:2430-9.
21. Bellail AC, Hunter SB, Brat DJ, Tan C, VanMeir EG. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol 2004;36:1046-69.
22. Bernstein JJ, Goldberg WJ, Laws ER Jr, Conger D, Morreale V, Wood LR. C6 glioma cell invasion and migration of rat brain after neural homografting: ultrastructure. Neurosurgery 1990;26:622-8.
23. Laws ER, Jr., Goldberg WJ, Bernstein JJ. Migration of human malignant astrocytoma cells in the mammalian brain: Scherer revisited. Int J Dev Neurosci 1993;1:691-7.
24. Giese A, Kluwe L, Laube B, Meissner H, Berens ME, Westphal M. Migration of human glioma cells on myelin. Neurosurgery 1996;38:755-64.
25. 1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology. Proc Natl Acad Sci USA 1998;95:14821-6.
26. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science 2001:294:1708-12.
27. Hotary KB, Allen ED, Brooks PC, Datta NS, Long MW, Weiss SJ. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell 2003;114:33-45.
28. Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem 2002;277:49481-7.
29. Maestro RD, Shivers R, McDonald W, Maestro AD. Dynamics of C6 astrocytoma invasion into three-dimensional collagen gels. J Neurooncol 2001;53:87-98.
30. Le DM, Besson A, Fogg DK, et al. Exploitation of astrocytes by glioma cells to facilitate invasiveness: a mechanism involving matrix metalloproteinase-2 and the urokinase-type plasminogen activator-plasmin cascade. J Neurosci 2003;23:4034-43.
31. Uhm JH, Dooley NP, Villemure JG, Yong VW. Glioma invasion in vitro: regulation by matrix metalloprotease-2 and protein kinase C. Clin Exp Metastasis 1996;14:421-33.
32. Graeber MB, Scheithauer BW, Kreutzberg GW. Microglia in brain tumors. Glia 2002;40:252-9.
33. Shipley JM, Wesselschmidt RL, Kobayashi DK, Ley TJ, Shapiro SD. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc Natl Acad Sci USA 1996;93:3942-6.
34. Wegrowski Y, Maquart FX. Involvement of stromal proteoglycans in tumour progression. Crit Rev Oncol Hematol 2004;49:259-68.
35. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429-47.
36. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001;7:14-23.
37. Kachra Z, Beaulieu E, Delbecchi L, et al. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis 1999;17:555-66.
38. Zagzag D, Friedlander DR, Dosik J, et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996;56:182-9.
39. Deryugina EI, Bourdon MA. Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci 1996;109:643-52.
40. Giese A, Loo MA, Norman SA, Treasurywala S, Berens ME. Contrasting migratory response of astrocytma cells to tenascin mediated by different integrins. J Cell Sci 1996;109:2161-8.
41. Phillips GR, Krushel LA, Crossin KL. Domains of tenascin involved in glioma migration. J Cell Sci 1998:111:1095-104.
42. Chen YE. MMP-12, an old enzyme plays a new role in the pathogenesis of rheumatoid arthritis? Am J Pathol 2004;165:1069-70.
43. Price A, Shi Q, Morris D, et al. Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Clin Cancer Res 1999;5:845-54.
44. Yoshida D, Watanabe K, Noha M, Takahashi H, Teramoto A, Sugisaki Y. Tracking cell invasion of human glioma cells and suppression by anti-matrix metalloproteinase agent in rodent brain-slice model. Brain Tumor Pathol 2002;19:69-76.
45. Bello L, Giussani C, Carrabba G, et al. Suppression of malignant glioma recurrence in a newly developed animal model by endogenous inhibitors. Clin Cancer Res 2002;8:3539-48.
46. Larson DA, Prados M, Lamborn KR, et al. Phase 11 study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys 2002;54:1397-404.
47. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002;20:1383-8.
48. Tremont-Lukats IW, Gilbert MR. Advances in molecular therapies in patients with brain tumors. Cancer Control 2003;10:125-37.
49. Levin VA, Phuphanich S, Alfred Yung WK, et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation. J Neurooncol 2006;78:295-302.
50. Zhang I, Sarkar S, Yong VW. The chemokine strornal cell derived factor-1 (CXCL 12) promotes glioma invasiveness through MT2-niatrix metalloproteinase. Carcinogenesis 2005;26:2069-77.